Drug Trial Radar · NCT07157787
Study of ALXN1920 in Adult Participants With Primary Membranous Nephropathy (PMN)
Last checked: Nov 20, 2026Latest source record: Jun 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
30
Planned (sponsor's estimate)
Start
Sep 19, 2025
Primary completion
Jul 2, 2027
Study completion Jul 9, 2027
Sponsor
- Lead sponsor
- Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
- Sponsor type
- Industry
- Collaborators
- AstraZeneca
- First posted
- Sep 5, 2025
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The primary objective of this study is to evaluate the efficacy of ALXN1920 compared with placebo in participants with PMN who are at a high risk for disease progression using 24-hour urine protein creatinine ratio (UPCR).
Conditions
- Primary Membranous Nephropathy
Interventions
ALXN1920Drug
Participants will receive ALXN1920 SC infusion.
PlaceboDrug
Participants will receive Placebo SC infusion.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Change From Baseline in Proteinuria Based on 24-hour UPCR at Week 26Time frame: Baseline, Week 26
Locations
40 sites in 10 countries. Site status is shown where the registry gives one.
Research Site
Loma Linda, California · Recruiting
Research Site
San Diego, California · Recruiting
Research Site
Minneapolis, Minnesota · Recruiting
Research Site
Rochester, Minnesota · Recruiting
Research Site
Houston, Texas · Recruiting
Research Site
Buenos Aires, Argentina · Recruiting
Research Site
CABA, Argentina · Recruiting
Research Site
Ciudad de Buenos Aires, Argentina · Recruiting
Research Site
La Plata, Argentina · Not yet recruiting
Research Site
Rosario, Argentina · Recruiting
Research Site
Santa Fe, Argentina · Withdrawn
Research Site
Santa Fe, Argentina · Withdrawn
Research Site
Gosford, Australia · Active not recruiting
Research Site
Parkville, Australia · Recruiting
Research Site
Southport, Australia · Recruiting
Research Site
Recife, Brazil · Recruiting
Research Site
Salvador, Brazil · Recruiting
Research Site
São Paulo, Brazil · Recruiting
Research Site
São Paulo, Brazil · Recruiting
Research Site
Baotou, China · Recruiting
Research Site
Beijing, China · Recruiting
Research Site
Guangzhou, China · Recruiting
Research Site
Shenzhen, China · Recruiting
Research Site
Créteil, France · Withdrawn
Research Site
Nice, France · Recruiting
Research Site
Toulouse, France · Recruiting
Research Site
Milan, Italy · Recruiting
Research Site
Ranica, Italy · Recruiting
Research Site
Torrette, Italy · Recruiting
Research Site
Barcelona, Spain · Recruiting
Research Site
Madrid, Spain · Recruiting
Research Site
Seville, Spain · Recruiting
Research Site
Toledo, Spain · Recruiting
Research Site
Kaohsiung City, Taiwan · Recruiting
Research Site
Taichung, Taiwan · Recruiting
Research Site
Taoyuan, Taiwan · Recruiting
Research Site
Cambridge, United Kingdom · Recruiting
Research Site
Leicester, United Kingdom · Recruiting
Research Site
London, United Kingdom · Recruiting
Research Site
Salford, United Kingdom · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.